Mogrify

Description

Mogrify develops platform technologies for direct cellular reprogramming that analyze transcriptomic, gene regulatory, and epigenetic data to predict transcription factors and culture media, producing target cell types for in vivo therapies in otology, ophthalmology, and diabetes.

Mogrify is located in the Cambridge ecosystem.

Related

• TQ TherapeuticsTQ Therapeutics operates a CELLfinity platform that delivers in vivo cell and gene therapies using a proprietary EXiVO automated approach…
• AAsgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
• ORF GeneticsORF Genetics produces animal-free, plant-made recombinant growth factors and cytokines used to support human cell cultures, skincare…
• Constructive BioConstructive Bio designs and manufactures new-to-nature proteins using expanded genetic code and programmable cellular manufacturing for…
• NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
• STORM TherapeuticsSTORM Therapeutics develops small molecule inhibitors of RNA-modifying enzymes, including STC-15, a METTL3 inhibitor in clinical…
• Orakl OncologyOrakl Oncology builds an AIxBio engine that analyzes multimodal patient data and living biological samples to predict drug responses,…
• MundipharmaMundipharma shares corporate, patient-centric, sustainability, finance, and consumer health resources, alongside medicine availability and…
• ActiTrexxActiTrexx develops therapies based on activated regulatory T cells for autoimmune and autoinflammatory diseases, including ATreg/Actileucel…